LLY ▼ -2.0% - Eli Lilly and Company $LLY - Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study 30-SEP-2026 06:00 PM ET